Bristol-Myers Squibb, Merck License New AIDS Drugs to International Partnership for Microbicides
November 1, 2005
Bristol-Myers Squibb and Merck on Monday agreed to license to the International Partnership for Microbicides four experimental antiretroviral treatments to be formulated and tested as microbicides that could help prevent HIV infection among women, the San Francisco Chronicle reports. Under the agreement, Merck will license three of the experimental drugs and BMS will license one to the organization. All four drugs are from a new class of antiretrovirals called entry inhibitors that help prevent HIV from entering the immune system cells it normally invades (Russell, San Francisco Chronicle, 11/1). The licenses, which are royalty-free, provide IPM with the rights to distribute the compounds in developing countries (Chase, Wall Street Journal, 11/1). The agreements mark the first time large pharmaceutical companies have signed on to help develop microbicides (Fox, Reuters UK, 10/31). Microbicides include a range of products -- such as gels, films, sponges and other products -- that could help prevent the sexual transmission of HIV and other sexually transmitted diseases in women (Kaiser Daily HIV/AIDS Report, 9/22).
Effectiveness of Female Controlled Barrier Methods in Preventing Sexually Transmitted Infections and HIV: Current Evidence and Future Research Directions
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.